WO2014048881A1 - Combination of regorafenib and acetylsalicylic acid for treating cancer - Google Patents

Combination of regorafenib and acetylsalicylic acid for treating cancer Download PDF

Info

Publication number
WO2014048881A1
WO2014048881A1 PCT/EP2013/069735 EP2013069735W WO2014048881A1 WO 2014048881 A1 WO2014048881 A1 WO 2014048881A1 EP 2013069735 W EP2013069735 W EP 2013069735W WO 2014048881 A1 WO2014048881 A1 WO 2014048881A1
Authority
WO
WIPO (PCT)
Prior art keywords
combination
regorafenib
acid
acetylsalicylic acid
limited
Prior art date
Application number
PCT/EP2013/069735
Other languages
English (en)
French (fr)
Inventor
Olaf Weber
Karl Ziegelbauer
Original Assignee
Bayer Pharma Aktiengesellschaft
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2014048881(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to BR112015006686-0A priority Critical patent/BR112015006686B1/pt
Priority to AU2013322854A priority patent/AU2013322854B2/en
Priority to RS20181015A priority patent/RS57875B1/sr
Priority to SI201331181T priority patent/SI2900269T1/sl
Priority to CA2885688A priority patent/CA2885688C/en
Priority to NZ705860A priority patent/NZ705860A/en
Priority to KR1020157010519A priority patent/KR102210575B1/ko
Priority to US14/431,119 priority patent/US10898500B2/en
Priority to ES13770659.4T priority patent/ES2687985T3/es
Priority to PL13770659T priority patent/PL2900269T3/pl
Priority to LTEP13770659.4T priority patent/LT2900269T/lt
Priority to SG11201501963RA priority patent/SG11201501963RA/en
Priority to DK13770659.4T priority patent/DK2900269T3/en
Priority to MYPI2015700911A priority patent/MY183969A/en
Application filed by Bayer Pharma Aktiengesellschaft, Bayer Ag filed Critical Bayer Pharma Aktiengesellschaft
Priority to MX2015003728A priority patent/MX357035B/es
Priority to CN201380050150.7A priority patent/CN104994876A/zh
Priority to JP2015532437A priority patent/JP6294888B2/ja
Priority to EP13770659.4A priority patent/EP2900269B1/en
Priority to EA201500365A priority patent/EA032023B1/ru
Publication of WO2014048881A1 publication Critical patent/WO2014048881A1/en
Priority to IL237690A priority patent/IL237690B/en
Priority to PH12015500587A priority patent/PH12015500587A1/en
Priority to ZA2015/02840A priority patent/ZA201502840B/en
Priority to HK16102326.3A priority patent/HK1214169A1/zh
Priority to HRP20181462TT priority patent/HRP20181462T1/hr
Priority to CY181100976T priority patent/CY1120939T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to pharmaceutical compositions and combinations comprising regorafenib and acetylsalicylic acid, or a hydrate, solvate, metabolite or pharmaceutically acceptable salt thereof or a polymorph thereof for treating, preventing or managing diseases and conditions including hyperproliverative disorders such as cancer in humans and other mammals.
  • Regorafenib which is 4 ⁇ 4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy ⁇ - pyridine-2-carboxylic acid methylamide, a compound of formula (I)
  • flt-3 kinase signalling molecules is a potent anti-cancer and anti-angiogenic agent that possesses various activities including inhibitory activity on the VEGFR, PDGFR, raf, p38, and/or flt-3 kinase signalling molecules and it can be used in treating various diseases and conditions like hyper-proliferative disorders such as cancers, tumors, lymphomas, sarcomas and leukemias as described in WO 2005/009961. it is currently developed for the treatment of colorectal cancer and gastrointestinal stromal tumors.
  • Acetylsalicylic acid is a well-known drug which cannot only be used for treating pain or reducing the risk to develop a cardiovascular event or disease but there are also hints for reducing the risk of developing cancer diseases (Rothwell PM et al (2012) Short-term effects of daily acetylsalicylic acid on cancer incidence, mortality and non-vascular death: analysis of the time course of risks and benefits in 5 1 randomized controlled trials. Lancet. 379: 1602-1612).
  • acetylsalicylic acid can reduce metastasis of tumors effecting a reduction of mortality in particular in patients with colorectal cancer (Rothwell PM et al (2012) Effect of daily acetylsalicylic acid on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 379: 1591-1601).
  • Object of the present invention is the improvement of the cancer therapy by the administration of regorafenib and acetylsalicylic acid in combination.
  • the combination of regorafenib and acetylsalicylic acid shows a significant efficacy improvement over the sum of the monotherapies.
  • the profile o the side effects (e.g. hand- foot syndrome, elevated blood pressure, fatigue, diarrhea and mucosal inflammation) can be improved.
  • the present invention pertains to a combination comprising regorafenib which is the compound of the formula (I)
  • acetylsalicylic acid or a hydrate, solvate, metabolite or pharmaceutically acceptable salt of thereof, or a polymorph thereof.
  • the compound of formula (I) or “regorafenib” refer to 4- ⁇ 4- [( ⁇ [4-chloro-3- (trifluoromethyl)phenyl]amino ⁇ carbonyl)amino]-3-fluorophenoxy ⁇ -N-methylpyridine-2- carboxamide as depicted in formula (I).
  • Solvates for the purposes of the invention are those forms of the compounds or their salts where solvent molecules form a stoichiometric complex in the solid state and include, but are not limited to for example water, ethanol and methanol.
  • Hydrates are a specific form of solvates, where the solvent molecule is water. Hydrates of the compounds of the invention or their salts are stoichiometric compositions of the compounds or salts with water, such as, for example, hemi-, mono- or dihydrates. Preference is given to the monohydrate of regorafenib.
  • Salts for the purposes of the present invention are preferably pharmaceutically acceptable salts of the compounds according to the invention.
  • Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulphonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, >-toluenesulfonic acid (tosylate salt), 1 - naphthalenesulfonic acid, 2-naphthalenesulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid.
  • salts of inorganic bases include salts containing alkaline cations (e.g., Lr a + or K ⁇ ), alkaline earth cations (e.g., Mg +2 , Ca +2 or Ba +2 ), the ammonium cation, as well as acid salts of organic bases, including aliphatic and aromatic substituted ammonium, and quaternary ammonium cations, such as those arising from protonation or peralkylation of triethylamine, NN-diethylamine, N,A r -dicyclohexylamine, lysine, pyridine, N,N-dimethylaminopyridine (DMAP), 1,4- diazabiclo[2.2.2]octane (DABCO), l,5-diazabicyclo[4.3.0]non-5-ene (DBN) and 1,8- diazabicyclo[5.4.0]undec-7-ene
  • alkaline cations e
  • regorafenib for the purpose of the present invention include 4-[4-( ⁇ [4-chloro-3- (trifluoromethyl)phenyl]carbamoyl ⁇ amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide 1 - oxide, 4-[4-( ⁇ [4-chloro-3-(trifluoromethyl)phenyl]carbamoyl ⁇ amino)-3-fluorophenoxy]- - (hydroxymethyl)pyridine-2-carboxamide, 4-[4-( ⁇ [4-chloro-3- (trifluoromethyl)phenyl]carbamoyl ⁇ amino)-3-fluorophenoxy]pyridine-2-carboxamide and 4- [4- ( ⁇ [4-chloro-3 -(trifluoromethyl)phenyljcarbamo
  • regorafenib and the monohydrate of regorafenib as a compound o the present invention.
  • the compounds of the invention may be prepared by use of known chemical reactions and procedures. Method for treatment:
  • the present invention also relates to a method for using the combination and compositions thereof, to treat mammalian hyper-proliferative disorders.
  • This method comprises administering to a mammal in need thereof, including a human, an amount of the combination, which is effective to treat the disorder.
  • Hyper-proliferative disorders include but are not limited to solid tumors, such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases. Those disorders also include lymphomas, sarcomas, and leukemias.
  • breast cancer examples include, but are not limited to invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ.
  • cancers of the respiratory tract include, but are not limited to small-cell and non- small-cell lung carcinoma, as well as bronchial adenoma and p!europu!monary blastoma.
  • brain cancers include, but are not limited to brain stem and hypophtalmic glioma, cerebellar and cerebral astrocytoma, medulloblastoma, ependymoma, as well as neuroectodermal and pineal tumor.
  • Tumors of the male reproductive organs include, but are not limited to prostate and testicular cancer.
  • Tumors of the female reproductive organs include, but are not limited to endometrial, cervical, ovarian, vaginal, and vulvar cancer, as well as sarcoma of the uterus.
  • Tumors of the digestive tract include, but are not limited to anal, colon, colorectal, esophageal, gallbladder, gastric, pancreatic, rectal, small intestine, and salivary gland cancers.
  • GIST gastrointestinal stromal tumors
  • Tumors of the urinary tract include, but are not limited to bladder, penile, kidney, renal pelvis, ureter, and urethral cancers.
  • Eye cancers include, but are not limited to intraocular melanoma and retinoblastoma.
  • liver cancers include, but are not limited to hepatocellular carcinoma (liver cell carcinomas with or without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), and mixed hepatocellular cholangiocarcinoma.
  • Preference is given to hepatic cell cancer.
  • Skin cancers include, but are not limited to squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma skin cancer.
  • Head-and-neck cancers include, but are not limited to laryngeal / hypopharyngeal / nasopharyngeal / oropharyngeal cancer, and lip and oral cavity cancer.
  • Lymphomas include, but are not limited to AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Hodgkin's disease, and lymphoma of the central nervous system.
  • Sarcomas include, but are not limited to sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.
  • Leukemias include, but are not limited to acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia. These disorders have been well characterized in humans, but also exist with a similar etiology in other mammals, and can be treated by administering pharmaceutical compositions of the present invention.
  • the effective dosage of the compounds of this invention can readily be determined for treatment of each desired indication.
  • the amount of the active ingredient to be administered in the treatment of one o these conditions can vary widely according to such considerations as the particular compound and dosage unit employed, the mode of administration, the period of treatment, the age and sex of the patient treated, and the nature and extent of the condition treated.
  • the present invention further provides the use of the compound of the invention for the preparation of a pharmaceutical compositions for the treatment of the aforesaid disorders.
  • Administration
  • Combinations of the present invention can be administered in any form by any effective route, including, e.g., oral, parenteral, enteral, intravenous, intraperitoneal, topical, transdermal (e.g., using any standard patch), ophthalmic, nasally, local, non-oral, such as aerosal, inhalation, subcutaneous, intramuscular, buccal, sublingual, rectal, vaginal, intra-arterial, and intrathecal, etc. They can be administered alone, or in combination with any ingredient(s), active or inactive.
  • acetylsalicylic acid can be administered intravenously.
  • Combinations o the present invention can be converted in a known manner into the usual formulations, which may be liquid or solid formulations e.g. without limitation normal and enteric coated tablets, capsules, pills, powders, granules, elixirs, tinctures, solution, suspensions, syrups, solid and liquid aerosols and emulsions.
  • formulations which may be liquid or solid formulations e.g. without limitation normal and enteric coated tablets, capsules, pills, powders, granules, elixirs, tinctures, solution, suspensions, syrups, solid and liquid aerosols and emulsions.
  • the use of the combinations of the present invention mentioned before will serve to: (1) yield better efficacy in reducing the growth of a tumor or even eliminate the tumor as compared to administration of either agent alone,
  • “Combination” means for the purposes of the invention not only a dosage form which contains all the components (so-called fixed combinations), and combination packs containing the components separate from one another, but also components which are administered simultaneously or sequentially, as long as they are employed for the prophylaxis or treatment of the same disease.
  • the amount of the administered active ingredient can vary widely according to such considerations as the particular compound and dosage unit employed, the mode and time o administration, the period of treatment, the age, sex, and general condition of the patient treated, the nature and extent of the condition treated, the rate of drug metabolism and excretion, the potential drug combinations and drug-drug interactions, and the like.
  • An aspect of the invention of particular interest is a combintaion comprising regorafenib in an amount of 4 to 400 mg, preferably from 10 to 200 mg, more preferably from 10 to 100 mg.
  • a further aspect of the invention of particular interest is a combination comprising acetylsalicylic acid in an amount of 50 to 100 mg, preferably from 60 to 500 mg, more preferably from 70 to 350 mg.
  • Typical doses of acetylsalicylic acid are 78 mg, 81 mg, 100 mg, 325 mg, 500 mg and 1000 mg.
  • the daily dose of regorafenib is from 10 to 1000 mg, preferably 40 to 500 mg, more preferably 80 to 320 mg, e.g. 160 mg.
  • the daily dose of acetylsalicylic acid is from 50 to 1000 mg, preferably from 60 to 500 mg, more preferably from 70 to 350 mg.
  • Typical daily doses of acetylsalicylic acid are 78 mg, 81 mg, 100 mg, 325 mg, 500 mg and 1000 mg.
  • the pharmaceutical composition according to the invention is administered one or more, preferably up to three, more preferably up to two times per day. Preference is given to an administration via the oral route. With each administration the number of tablets or capsules taken in at the same time should not exceed two. Nevertheless, it may in some cases be advantageous to deviate from the amounts specified, depending on body weight, individual behaviour toward the active ingredient, type of preparation and time or interval over which the administration is affected. For instance, less than the aforementioned minimum amounts may be sufficient in some cases, while the upper limit specified has to be exceeded in other cases. In the case of administration of relatively large amounts, it may be advisable to divide these into several individual doses over the day.
  • Examples of an administration scheme are as follows: In the first cycle daily doses of 160 mg regorafenib and 81 mg acetylsalicylic acid are administered for 3 weeks. In week four only 81 mg acetylsalicylic acid are administered. Then the cycle can be repeated.
  • the daily dose of acetylsalicylic acid can be equal or less than 325 mg (e.g. 100 mg) or it can be more than 325 mg (e.g. 500 mg).
  • the combination can comprise effective amounts of the compound of Formula I and acetylsalicylic acid, which achieves a greater therapeutic efficacy than when either compound is used alone.
  • the relative ratios of each compound in the combination can also be selected based on their respective mechanisms of action and the disease biology.
  • the relative ratios of each compound can vary widely.
  • the release of one or more agents of the combination can also be controlled, where appropriate, to provide the desired therapeutic activity when in a single dosage form, combination pack, kit or when in separate independent dosage forms.
  • the present invention includes pharmaceutical compositions which are comprised of a pharmaceutically acceptable carrier and a pharmaceutically effective amount of the compounds of the present invention.
  • a pharmaceutically acceptable carrier is any carrier which is relatively nontoxic and innocuous to a patient at concentrations consistent with effective activity of the active ingredient so that any side effects ascribable to the carrier do not vitiate the beneficial effects of the active ingredient.
  • a pharmaceutically effective amount of compound is that amount which produces a result or exerts an influence on the particular condition being treated.
  • the compounds can be formulated into solid or liquid preparations such as solid dispersion, capsules, pills, tablets, troches, lozenges, melts, powders, solutions, suspensions, or emulsions, and may be prepared according to methods known to the art for the manufacture of pharmaceutical compositions.
  • the solid unit dosage forms can be a capsule which can be of the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers such as lactose, sucrose, calcium phosphate, and corn starch.
  • the compounds of this invention may be tableted with conventional tablet bases such as lactose, sucrose and cornstarch in combination with binders such as acacia, corn starch or gelatin, disintegrating agents intended to assist the break-up and dissolution of the tablet following administration such as potato starch, alginic acid, corn starch, and guar gum, gum tragacanth, acacia, lubricants intended to improve the flow o tablet granulation and to prevent the adhesion of tablet material to the surfaces of the tablet dies and punches, for example talc, stearic acid, or magnesium, calcium or zinc stearate, dyes, coloring agents, and flavoring agents such as peppermint, oil of wintergreen, or cherry flavoring, intended to enhance the aesthetic qualities o the tablets and make them more acceptable to the patient.
  • binders such as acacia, corn starch or gelatin
  • disintegrating agents intended to assist the break-up and dissolution of the tablet following administration such as potato starch, alginic acid,
  • Suitable excipients for use in oral liquid dosage forms include dicalcium phosphate and diluents such as water and alcohols, for example, ethanol, benzyl alcohol, and polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent or emulsifying agent.
  • Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance tablets, pills or capsules may be coated with shellac, sugar or both.
  • Dispersibie powders and granules are suitable for the preparation of an aqueous suspension. They provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example those sweetening, flavoring and coloring agents described above, may also be present.
  • the pharmaceutical compositions of this invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil such as liquid paraffin or a mixture of vegetable oils.
  • Suitable emulsifying agents may be (1) naturally occurring gums such as gum acacia and gum tragacanth, (2) naturally occurring phosphatides such as soy bean and lecithin, (3) esters or partial esters derived form fatty acids and hexitol anhydrides, for example, sorbitan monooleate, (4) condensation products of said partial esters with ethylene oxide, for example, polyoxy ethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavoring agents.
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil such as, for example, arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent such as, for example, beeswax, hard paraffin, or cetyl alcohol.
  • the suspensions may also contain one or more preservatives, for example, ethyl or ⁇ -propyl p-hydroxybenzoate; one or more coloring agents; one or more flavoring agents; and one or more sweetening agents such as sucrose or saccharin.
  • Syrups and elixirs may be formulated with sweetening agents such as, for example, glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, and preservative, such as methyl and propyl parabens and flavoring and coloring agents.
  • sweetening agents such as, for example, glycerol, propylene glycol, sorbitol or sucrose.
  • Such formulations may also contain a demulcent, and preservative, such as methyl and propyl parabens and flavoring and coloring agents.
  • the compounds of this invention may also be administered parenterally, that is, subcutaneously, intravenously, intraocularly, intrasynovially, intramuscularly, or interperitoneally, as injectable dosages of the compound in a physiologically acceptable diluent with a pharmaceutical carrier which can be a sterile liquid or mixture of liquids such as water, saline, aqueous dextrose and related sugar solutions, an alcohol such as ethanol, isopropanol, or hexadecyl alcohol, glycols such as propylene glycol or polyethylene glycol, glycerol ketals such as 2,2-dimethyl-l ,1 -dioxolane-4- methanol, ethers such as poly(ethylene glycol) 400, an oil, a fatty acid, a fatty acid ester or, a fatty acid glyceride, or an acetylated fatty acid glyceride, with or without the addition of a pharmaceutically acceptable surfact
  • Illustrative o oils which can be used in the parenteral formulations of this invention are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, sesame oil, cottonseed oil, corn oil, olive oil, petrolatum and mineral oil.
  • Suitable fatty acids include oleic acid, stearic acid, isostearic acid and myristic acid.
  • Suitable fatty acid esters are, for example, ethyl oleate and isopropyl myristate.
  • Suitable soaps include fatty acid alkali metal, ammonium, and triethanolamine salts and suitable detergents include cationic detergents, for example dimethyl dialkyl ammonium halides, alkyl pyridinium halides, and alkylamine acetates; anionic detergents, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates; non-ionic detergents, for example, fatty amine oxides, fatty acid alkanolamides, and poly(oxyethylene-oxypropylene)s or ethylene oxide or propylene oxide copolymers; and amphoteric detergents, for example, alkyl-beta-aminopropionates, and 2-alkylimidazoline quarternary ammonium salts, as well as mixtures.
  • suitable detergents include cationic detergents, for example di
  • compositions of this invention will typically contain from about 0.5% to about 25% by weight of the active ingredient in solution. Preservatives and buffers may also be used advantageously. In order to minimize or eliminate irritation at the site of injection, such compositions may contain a non-ionic surfactant having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulation ranges from about 5% to about 15% by weight.
  • the surfactant can be a single component having the above HLB or can be a mixture of two or more components having the desired 1 II B.
  • surfactants used in parenteral formulations are the class of polyethylene sorbitan fatty acid esters, for example, sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.
  • compositions may be in the form of sterile injectable aqueous suspensions.
  • suspensions may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents such as, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents which may be a naturally occurring phosphatide such as lecithin, a condensation product of an alkylene oxide with a fatty acid, for example, polyoxy ethylene stearate, a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example, heptadeca-ethyleneoxycetanol, a condensation product of ethylene oxide with a partial ester derived form a fatty acid and a hexitol such as polyoxy ethylene sorbitol monooleate, or a condensation product of an ethylene oxide with a partial ester derived from
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent.
  • Diluents and solvents that may be employed are, for example, water, Ringer's solution, isotonic sodium chloride solutions and isotonic glucose solutions.
  • sterile fixed oils are conventionally employed as solvents or suspending media.
  • any bland, fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid can be used in the preparation of injectables.
  • compositions of the invention may also be administered in the form of suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non-irritation excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • a suitable non-irritation excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • a suitable non-irritation excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such material is, for example, cocoa butter and polyethylene glycol.
  • Controlled release formulations for parenteral administration include liposomal, polymeric microsphere and polymeric gel formulations which are known in the art.
  • compositions of this invention may also be in the form o a solid dispersion.
  • the solid dispersion may be a solid solution, glass solution, glass suspension, amorphous precipitation in a crystalline carrier, eutectic or monotecic, compound or complex formation and combinations thereof.
  • An aspect of the invention of particular interest is a pharmaceutical composition
  • a pharmaceutical composition comprising a solid dispersion, wherein the matrix comprises a pharmaceutically acceptable polymer, such as polyvinylpyrrolidone, vinylpyrrolidone/vinylacetate copolymer, polyalkylene glycol (i.e. polyethylene glycol), hydroxyalkyl cellulose (i.e. hydroxypropyl cellulose), hydroxyalkyl methyl cellulose (i.e.
  • a pharmaceutically acceptable polymer such as polyvinylpyrrolidone, vinylpyrrolidone/vinylacetate copolymer, polyalkylene glycol (i.e. polyethylene glycol), hydroxyalkyl cellulose (i.e. hydroxypropyl cellulose), hydroxyalkyl methyl cellulose (i.e.
  • hydroxypropyl methyl cellulose carboxymethyl cellulose, sodium carboxymethyl cellulose, ethyl cellulose, polymethacrylates, polyvinyl alcohol, polyvinyl acetate, vinyl alcohol/vinyl acetate copolymer, polyglycolized glycerides, xanthan gum, carrageen an. chitosan, chitin, poyldextrin, dextrin, starch and proteins.
  • compositions comprising a solid dispersion, wherein the matrix comprises a sugar and/or sugar alcohol and/or cyclodextrin, for example sucrose, lactose, fructose, maltose, raffinose, sorbitol, lactitol, mannitol, maltitol, erythritol, inositol, trehalose, isomalt, inulin, maltodextrin, ⁇ -cyclodextrin, hydroxypropyl- -cyclodextrin or sulfobutyl ether cyclodextrin.
  • a sugar and/or sugar alcohol and/or cyclodextrin for example sucrose, lactose, fructose, maltose, raffinose, sorbitol, lactitol, mannitol, maltitol, erythritol, inositol, treha
  • Additional suitable carriers that are useful in the formation of the matrix of the solid dispersion include, but are not limited to alcohols, organic acids, organic bases, amino acids, phospholipids, waxes, salts, fatty acid esters, polyoxy ethylene sorbitan fatty acid esters, and urea.
  • the solid dispersion of regorafenib in the matrix may contain certain additional pharmaceutical acceptable ingredients, such as surfactants, fillers, disintegrants, recrystallization inhibitors, plasticizers, defoamers, antioxidants, detackifier, pH-modifiers, glidants and lubricants.
  • additional pharmaceutical acceptable ingredients such as surfactants, fillers, disintegrants, recrystallization inhibitors, plasticizers, defoamers, antioxidants, detackifier, pH-modifiers, glidants and lubricants.
  • the solid dispersion of the invention is prepared according to methods known to the art for the manufacture of solid dispersions, such as fusion/melt technology, hot melt extrusion, solvent evaporation (i.e. freeze drying, spray drying or layering of powders of granules), coprecipitation, supercritical fluid technology and electrostatic spinning method.
  • the compositions of the invention can also contain other conventional pharmaceutically acceptable compounding ingredients, generally referred to as carriers or diluents, as necessary or desired. Conventional procedures for preparing such compositions in appropriate dosage forms can be utilized.
  • Commonly used pharmaceutical ingredients which can be used as appropriate to formulate the composition for its intended route of administration include: acidifying agents (examples include but are not limited to acetic acid, citric acid, fumaric acid, hydrochloric acid, nitric acid); alkalini/ing agents (examples include but are not limited to ammonia solution, ammonium carbonate, diethanolamine, monoethanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium hydroxide, triethanolamine, trolamine); adsorbents (examples include but are not limited to powdered cellulose and activated charcoal); aerosol propeilants (examples include but are not limited to carbon dioxide, CCI2F2, air displacement agents (examples include but are not limited to nitrogen and argon); antifungal preservatives (examples include but are not limited to benzoic acid, butylparaben, ethylparaben, methylparaben, propylparaben, sodium benzoate
  • amides, ethers, ketones and ureas) piasticizers examples include but are not limited to diethyl phthalate and glycerol
  • solvents examples include but are not limited to ethanol, corn oil, cottonseed oil, glycerol, isopropanol, mineral oil, oleic acid, peanut oil, purified water, water for injection, sterile water for injection and sterile water for irrigation
  • stiffening agents include but are not limited to cetyl alcohol, cetyl esters wax, microcrystalline wax, paraffin, stearyl alcohol, white wax and yellow wax
  • suppository bases examples include but are not limited to cocoa butter and polyethylene glycols (mixtures)
  • surfactants examples include but are not limited to benzalkonium chloride, nonoxynol 10, oxtoxynol 9, polysorbate 80, sodium lauryl sulfate and sorbitan mono-palmitate); suspend

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/EP2013/069735 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating cancer WO2014048881A1 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
AU2013322854A AU2013322854B2 (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating cancer
MYPI2015700911A MY183969A (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating cancer
DK13770659.4T DK2900269T3 (en) 2012-09-25 2013-09-23 COMBINATION OF REGORAFENIB AND ACETYLSALICYLIC ACID FOR TREATMENT OF COLORECTAL CANCER.
SI201331181T SI2900269T1 (sl) 2012-09-25 2013-09-23 Kombinacija regorafeniba in acetilsalicilne kisline za zdravljenje kolorektalnega raka
CA2885688A CA2885688C (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating cancer
NZ705860A NZ705860A (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating cancer
KR1020157010519A KR102210575B1 (ko) 2012-09-25 2013-09-23 암 치료를 위한 레고라페닙과 아세틸살리실산의 조합물
US14/431,119 US10898500B2 (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating cancer
ES13770659.4T ES2687985T3 (es) 2012-09-25 2013-09-23 Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer colorrectal
PL13770659T PL2900269T3 (pl) 2012-09-25 2013-09-23 Połączenie regorafenibu i kwasu acetylosalicylowego do leczenia raka jelita grubego
LTEP13770659.4T LT2900269T (lt) 2012-09-25 2013-09-23 Regorafenibo ir acetilsalicilo rūgšties derinys kolorektalinio vėžio gydymui
SG11201501963RA SG11201501963RA (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating cancer
RS20181015A RS57875B1 (sr) 2012-09-25 2013-09-23 Kombinacija regorafeniba i acetilsalicilne kiseline za lečenje kolorektalnog kancera
BR112015006686-0A BR112015006686B1 (pt) 2012-09-25 2013-09-23 Combinação de regorafenib e ácido acetilsalicílico para tratamento de câncer coloretal
EA201500365A EA032023B1 (ru) 2012-09-25 2013-09-23 Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
MX2015003728A MX357035B (es) 2012-09-25 2013-09-23 Combinacion de regorafenib y acido acetilsalicilico para el tratamiento del cancer.
CN201380050150.7A CN104994876A (zh) 2012-09-25 2013-09-23 用于治疗癌症的瑞戈非尼和乙酰水杨酸的组合
JP2015532437A JP6294888B2 (ja) 2012-09-25 2013-09-23 癌を治療するためのレゴラフェニブおよびアセチルサリチル酸の組み合わせ
EP13770659.4A EP2900269B1 (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating colorectal cancer
IL237690A IL237690B (en) 2012-09-25 2015-03-12 A combination of regorfenib and acetylsalicylic acid for the treatment of cancer
PH12015500587A PH12015500587A1 (en) 2012-09-25 2015-03-17 Combination of regorafenib and acetylsalicylic acid for treating cancer
ZA2015/02840A ZA201502840B (en) 2012-09-25 2015-04-24 Combination of regorafenib and acetylsalicylic acid for treating cancer
HK16102326.3A HK1214169A1 (zh) 2012-09-25 2016-03-01 用於治療癌症的瑞戈非尼和乙酰水楊酸的組合
HRP20181462TT HRP20181462T1 (hr) 2012-09-25 2018-09-12 Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva
CY181100976T CY1120939T1 (el) 2012-09-25 2018-09-20 Συνδυασμος ρεγοραφενιμπης και ακετυλοσαλικυλικου οξεος για τη θεραπευτικη αντιμετωπιση του ορθοκολικου καρκινου

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12185852 2012-09-25
EP12185852.6 2012-09-25

Publications (1)

Publication Number Publication Date
WO2014048881A1 true WO2014048881A1 (en) 2014-04-03

Family

ID=46963566

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/069735 WO2014048881A1 (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating cancer

Country Status (29)

Country Link
US (1) US10898500B2 (pt-PT)
EP (1) EP2900269B1 (pt-PT)
JP (1) JP6294888B2 (pt-PT)
KR (1) KR102210575B1 (pt-PT)
CN (1) CN104994876A (pt-PT)
AU (1) AU2013322854B2 (pt-PT)
BR (1) BR112015006686B1 (pt-PT)
CA (1) CA2885688C (pt-PT)
CL (1) CL2015000744A1 (pt-PT)
CY (1) CY1120939T1 (pt-PT)
DK (1) DK2900269T3 (pt-PT)
EA (1) EA032023B1 (pt-PT)
ES (1) ES2687985T3 (pt-PT)
HK (1) HK1214169A1 (pt-PT)
HR (1) HRP20181462T1 (pt-PT)
HU (1) HUE039878T2 (pt-PT)
IL (1) IL237690B (pt-PT)
LT (1) LT2900269T (pt-PT)
MX (1) MX357035B (pt-PT)
MY (1) MY183969A (pt-PT)
NZ (1) NZ705860A (pt-PT)
PH (1) PH12015500587A1 (pt-PT)
PL (1) PL2900269T3 (pt-PT)
PT (1) PT2900269T (pt-PT)
RS (1) RS57875B1 (pt-PT)
SG (2) SG11201501963RA (pt-PT)
SI (1) SI2900269T1 (pt-PT)
WO (1) WO2014048881A1 (pt-PT)
ZA (1) ZA201502840B (pt-PT)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103923001A (zh) * 2014-04-30 2014-07-16 药源药物化学（上海）有限公司 瑞戈非尼盐及其晶型、制备方法
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
US9802944B2 (en) 2014-03-26 2017-10-31 Hoffmann-La Roche Inc. Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
WO2018219807A1 (en) * 2017-06-02 2018-12-06 Bayer Aktiengesellschaft Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
US10633384B2 (en) 2012-06-13 2020-04-28 Hoffmann-La Roche Inc. Diazaspirocycloalkane and azaspirocycloalkane
US10640472B2 (en) 2015-09-04 2020-05-05 Hoffman-La Roche Inc. Phenoxymethyl derivatives
US10647719B2 (en) 2015-09-24 2020-05-12 Hoffmann-La Roche Inc. Bicyclic compounds as dual ATX/CA inhibitors
US10669268B2 (en) 2012-09-25 2020-06-02 Hoffmann-La Roche Inc. Bicyclic derivatives
US10669285B2 (en) 2014-03-26 2020-06-02 Hoffmann-La Roche Inc. Condensed [1,4] diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
US10676446B2 (en) 2015-04-10 2020-06-09 Hoffmann-La Roche Inc. Bicyclic quinazolinone derivatives
US10738053B2 (en) 2015-09-24 2020-08-11 Hoffmann-La Roche Inc. Bicyclic compounds as dual ATX/CA inhibitors
US10787459B2 (en) 2015-09-24 2020-09-29 Hoffmann-La Roche Inc. Bicyclic compounds as ATX inhibitors
US10800786B2 (en) 2015-09-24 2020-10-13 Hoffman-La Roche Inc. Bicyclic compounds as ATX inhibitors
US10849881B2 (en) 2013-11-26 2020-12-01 Hoffmann-La Roche Inc. Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl
US10882857B2 (en) 2017-03-16 2021-01-05 Hoffmann-La Roche Inc. Bicyclic compounds as ATX inhibitors
US10913745B2 (en) 2013-03-12 2021-02-09 Hoffmann-La Roche Inc. Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors
US11059794B2 (en) 2017-03-16 2021-07-13 Hoffmann-La Roche Inc. Heterocyclic compounds useful as dual ATX/CA inhibitors
US11844806B2 (en) 2017-12-22 2023-12-19 Asamedic As Compositions comprising acetylsalicylic acid and a phosphate salt
US11850253B2 (en) 2017-12-22 2023-12-26 Asamedic As Two component compositions
US11918554B2 (en) * 2016-06-28 2024-03-05 Asamedic As Two-component composition

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210156389A (ko) 2020-06-17 2021-12-27 재단법인대구경북과학기술원 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20050038080A1 (en) * 2003-07-23 2005-02-17 Stephen Boyer Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2007054303A2 (en) * 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryl urea for treating diabetic neuropathy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1197228A4 (en) * 1999-07-02 2004-03-10 Hisamitsu Pharmaceutical Co DRUG COMPOSITIONS FOR THE TREATMENT OF COLORECTAL CANCER
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
GB201002530D0 (en) * 2010-02-15 2010-03-31 Univ Wolverhampton The Di-aspirin derivatives
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20050038080A1 (en) * 2003-07-23 2005-02-17 Stephen Boyer Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2007054303A2 (en) * 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryl urea for treating diabetic neuropathy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AXEL GROTHEY ET AL: "Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial for the CORRECT Study Group", vol. 381, no. 9863, 26 January 2013 (2013-01-26), England, pages 303 - 312, XP055085767, ISSN: 1474-547X, Retrieved from the Internet <URL:http://www.sciencedirect.com/science/article/pii/S014067361261900X/pdfft?md5=e17489b174c639b82e7af7ee8d13a5a6&pid=1-s2.0-S014067361261900X-main.pdf> [retrieved on 20131029], DOI: 10.1016/S0140-6736(12)61900-X *
J BURN ET AL: "Long-term eff ect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial", vol. 378, no. 9809, 17 December 2011 (2011-12-17), pages 2081 - 2087, XP055085755, Retrieved from the Internet <URL:http://www.sciencedirect.com/science/article/pii/S0140673611610490/pdfft?md5=19ba873b6a5e35d3b91007d03cd8334a&pid=1-s2.0-S0140673611610490-main.pdf> [retrieved on 20131029], DOI: 10.1016/S0140-6736(11)61049-0 *

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10633384B2 (en) 2012-06-13 2020-04-28 Hoffmann-La Roche Inc. Diazaspirocycloalkane and azaspirocycloalkane
US10669268B2 (en) 2012-09-25 2020-06-02 Hoffmann-La Roche Inc. Bicyclic derivatives
US10913745B2 (en) 2013-03-12 2021-02-09 Hoffmann-La Roche Inc. Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors
US10849881B2 (en) 2013-11-26 2020-12-01 Hoffmann-La Roche Inc. Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl
US11098048B2 (en) 2014-03-26 2021-08-24 Hoffmann-La Roche Inc. Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
US9802944B2 (en) 2014-03-26 2017-10-31 Hoffmann-La Roche Inc. Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
US10654857B2 (en) 2014-03-26 2020-05-19 Hoffman-La Roche Inc. Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
US10669285B2 (en) 2014-03-26 2020-06-02 Hoffmann-La Roche Inc. Condensed [1,4] diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
CN103923001A (zh) * 2014-04-30 2014-07-16 药源药物化学（上海）有限公司 瑞戈非尼盐及其晶型、制备方法
WO2015165320A1 (zh) * 2014-04-30 2015-11-05 药源药物化学（上海）有限公司 瑞戈非尼盐及其晶型、制备方法
CN104829523A (zh) * 2014-04-30 2015-08-12 药源药物化学（上海）有限公司 瑞戈非尼盐及其晶型、制备方法
US10676446B2 (en) 2015-04-10 2020-06-09 Hoffmann-La Roche Inc. Bicyclic quinazolinone derivatives
US11352330B2 (en) 2015-09-04 2022-06-07 Hoffmann-La Roche Inc. Phenoxymethyl derivatives
US10640472B2 (en) 2015-09-04 2020-05-05 Hoffman-La Roche Inc. Phenoxymethyl derivatives
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
US10800786B2 (en) 2015-09-24 2020-10-13 Hoffman-La Roche Inc. Bicyclic compounds as ATX inhibitors
US10787459B2 (en) 2015-09-24 2020-09-29 Hoffmann-La Roche Inc. Bicyclic compounds as ATX inhibitors
US10738053B2 (en) 2015-09-24 2020-08-11 Hoffmann-La Roche Inc. Bicyclic compounds as dual ATX/CA inhibitors
US10889588B2 (en) 2015-09-24 2021-01-12 Hoffmann-La Roche Inc. Bicyclic compounds as dual ATX/CA inhibitors
US10647719B2 (en) 2015-09-24 2020-05-12 Hoffmann-La Roche Inc. Bicyclic compounds as dual ATX/CA inhibitors
US11918554B2 (en) * 2016-06-28 2024-03-05 Asamedic As Two-component composition
US10882857B2 (en) 2017-03-16 2021-01-05 Hoffmann-La Roche Inc. Bicyclic compounds as ATX inhibitors
US11059794B2 (en) 2017-03-16 2021-07-13 Hoffmann-La Roche Inc. Heterocyclic compounds useful as dual ATX/CA inhibitors
US11673888B2 (en) 2017-03-16 2023-06-13 Hoffmann-La Roche Inc. Bicyclic compounds as ATX inhibitors
US11517622B2 (en) 2017-06-02 2022-12-06 Bayer Healthcare Llc Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
WO2018219807A1 (en) * 2017-06-02 2018-12-06 Bayer Aktiengesellschaft Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
AU2018276273B2 (en) * 2017-06-02 2023-12-21 Bayer Healthcare Llc Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
CN110662540B (zh) * 2017-06-02 2024-01-26 拜耳医药保健有限责任公司 用于治疗癌症的瑞格菲尼和pd-1/pd-l1(2)抑制剂的组合产品
CN110662540A (zh) * 2017-06-02 2020-01-07 拜耳股份公司 用于治疗癌症的瑞格菲尼和pd-1/pd-l1(2)抑制剂的组合产品
US11951166B2 (en) 2017-06-02 2024-04-09 Bayer Aktiengesellschaft Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
US11844806B2 (en) 2017-12-22 2023-12-19 Asamedic As Compositions comprising acetylsalicylic acid and a phosphate salt
US11850253B2 (en) 2017-12-22 2023-12-26 Asamedic As Two component compositions

Also Published As

Publication number Publication date
MY183969A (en) 2021-03-17
DK2900269T3 (en) 2018-10-01
MX357035B (es) 2018-06-25
IL237690B (en) 2019-07-31
CY1120939T1 (el) 2019-12-11
SI2900269T1 (sl) 2018-10-30
SG11201501963RA (en) 2015-04-29
PH12015500587A1 (en) 2015-05-11
HUE039878T2 (hu) 2019-02-28
CA2885688A1 (en) 2014-04-03
ZA201502840B (en) 2017-11-29
CL2015000744A1 (es) 2016-01-08
JP2015529234A (ja) 2015-10-05
CA2885688C (en) 2021-03-02
ES2687985T3 (es) 2018-10-30
HRP20181462T1 (hr) 2018-11-02
AU2013322854B2 (en) 2018-07-19
MX2015003728A (es) 2015-09-23
PL2900269T3 (pl) 2019-02-28
JP6294888B2 (ja) 2018-03-14
US10898500B2 (en) 2021-01-26
HK1214169A1 (zh) 2016-07-22
CN104994876A (zh) 2015-10-21
EA201500365A1 (ru) 2015-08-31
RS57875B1 (sr) 2018-12-31
AU2013322854A1 (en) 2015-04-02
KR102210575B1 (ko) 2021-02-02
EP2900269B1 (en) 2018-08-01
BR112015006686A2 (pt) 2019-08-27
IL237690A0 (en) 2015-05-31
PT2900269T (pt) 2018-10-22
KR20150060869A (ko) 2015-06-03
BR112015006686B1 (pt) 2022-04-05
US20150202214A1 (en) 2015-07-23
LT2900269T (lt) 2018-11-12
NZ705860A (en) 2018-07-27
SG10201702356VA (en) 2017-04-27
EP2900269A1 (en) 2015-08-05
EA032023B1 (ru) 2019-03-29

Similar Documents

Publication Publication Date Title
US10898500B2 (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
US20100113533A1 (en) Polymorph II of 4-[4-(Amino)-3- Fluorophenoxy]-N-Methylpyridine-2-Carboxamide
US20100063112A1 (en) Polymorph iii of 4-[4-(amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
JP7475402B2 (ja) 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用
RU2774838C2 (ru) Комбинация регорафениба и ингибиторов pd-1/pd-l1(2) для лечения рака
WO2021160708A1 (en) Combination of regorafenib and msln-ttc for treating cancer
JP2024096905A (ja) 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13770659

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2013770659

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 237690

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12015500587

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2885688

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2015532437

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2015000744

Country of ref document: CL

Ref document number: MX/A/2015/003728

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14431119

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2013322854

Country of ref document: AU

Date of ref document: 20130923

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20157010519

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201500365

Country of ref document: EA

Ref document number: IDP00201502504

Country of ref document: ID

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015006686

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112015006686

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150325